Boehringer Ingelheim Press Releases

Boehringer Ingelheim pursuing health care innovation – new collaboration with Healthrageous, Inc on a digital diabetes self-management program

Boehringer Ingelheim Establishes Translational Research Collaboration with Harvard University in Areas of Unmet Medical Need

Boehringer Ingelheim announces changes to Board of Managing Directors: Joachim Hasenmaier to lead new Board Division Consumer Healthcare and Animal Health

New publication in The Lancet: Two-year study in over 1,500 patients compares Trajenta® (linagliptin) to the commonly prescribed sulphonylurea glimepiride

No significant difference in the risk of Acute Coronary Syndrome (including Myocardial Infarction) seen with Pradaxa® (dabigatran etexilate) compared to enoxaparin for VTE prevention after orthopaedic surgery

First study to evaluate alternative to warfarin for mechanical heart valve patients launched with Pradaxa® (dabigatran etexilate)

AF patients who require surgery benefit from a shorter treatment interruption on dabigatran etexilate (Pradaxa®) compared to warfarin

Boehringer Ingelheim BioXcellence:
Distinctive brand for the biopharmaceutical contract manufacturing business

Boehringer Ingelheim once again certified as a family-friendly company

Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine

New analysis presented at ADA shows improvement in albuminuria with linagliptin in patients at high risk of declining renal function

New data demonstrate sustained glucose reduction and weight loss up to 90 weeks with investigational SGLT-2 inhibitor, empagliflozin*

New linagliptin phase III data demonstrate significant reductions in blood glucose with no additional risk of hypoglycaemia when combined with insulin in patients with type 2 diabetes

FDA affirms superiority of Pradaxa® (dabigatran etexilate) 150mg over warfarin in reduction of both ischaemic and haemorrhagic strokes

Boehringer Ingelheim and Lilly to feature 30 presentations on type 1 and type 2 diabetes at the 72^nd American Diabetes Association Scientific Sessions

Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial

Boehringer Ingelheim launches first-of-a-kind fundraising model to support disease awareness projects

Boehringer Ingelheim expands development capacities with new technical centre